Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 1 (1)
P 3 (1)

Trial Status

Unknown2
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07279909Phase 3Active Not Recruiting

Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation

NCT04488848Not ApplicableUnknownPrimary

Cardiometabolic Effects of Rapid Glucose Excursion

NCT00008801Phase 1Unknown

hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure

Showing all 3 trials

Research Network

Activity Timeline